Leo Pharma starts phase III hand eczema trial

Leo Pharma will test the effectivity of its treatment delgocitinib in treating chronic hand eczema in a phase III trial. It has high hopes for the indication.
Photo: Leo Pharma / PR
Photo: Leo Pharma / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT

After a positive phase II study, Leo Pharma has moved onto phase III trials for its eczema treatment delgocitinib. The first patients have been enrolled in the trial.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading